OBJECTIVE： To investigate the preventive and therapeutic effect of Shuganning injection on alcoholic liver fibrosis （ALF） in model rats， and provide experimental basis for its clinical application for alcoholic liver disease. METHODS： 50 rats were enrolled and intraperitoneally given mixed liquid of 60％ alcohol-corn oil-pyrazole to reduce ALF model. Another 10 rats were enrolled and intraperitoneally given normal saline， as normal control group. After 16 weeks， survived model rats （n＝40） were randomly divided into model group， positive control group （Anluo huaxian pill 0.75 g/kg， ig）， Shuganning injection high-dose， medium-dose， low-dose groups （4.8， 2.4， 1.2 mL/kg， ip）， 8 in each group. Normal control group and model group were intraperitoneally injected equal volume of normal saline （5 mL/kg）， administration groups were given relevant medicines， once a day， for 8 weeks； and modeling was contiuously conducted at the same time. After administration， body mass of rats was weighed， and the levels of liver function indexes [aspartate aminotransferase （AST）， alanine aminotransferase （ALT）] and liver fibrosis indexes [hyaluronic acid （HA）， laminin （LN）， type Ⅲ procollagen （PⅢNP）， type Ⅳ collagen （Ⅳ-C）] in serum of rats were detected. Liver index of rats was determined and pathological changes of liver tissue were observed. RESULTS： Compared with normal control group， body mass of rats in model group was significantly decreased （P＜0.05）； liver index， and liver function index， liver fibrosis index levels in serum were significantly increased （P＜0.05 or P＜0.01）. Liver tissue showed steatosis， hepatocyte vacuolization， a large number of fibrous tissue deposition around portal areas and other pathological changes. Compared with model group， above-mentioned changes were improved significantly in administration groups （P＜0.05 or P＜0.01）. CONCLUSIONS： Shuganning injection can obviously improve liver tissue damage of model rats with ALF， showing certain preventive and therapeutic effect on alcoholic liver disease.